S15 Ep43: Medical Crossfire®: The Who, When, and How of TROP2-Targeting ADCs, ICIs, and PARP Inhibition in Triple-Negative Breast Cancer
OncLive® On Air
00:00
Datopotamab deruxtecan: early TNBC activity
Heather McArthur reviews TROP2 ADC Dato‑DXD phase I data showing impressive responses, including in patients previously treated with SG.
Play episode from 13:57
Transcript
